Active substance
Trifluoperazine
- SFDA 6
- US FDA 24
- US price lines 4
- NHS prices 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| STELAZINE 1MG TABLETS | 1 mg | Tablet · Oral use | 50 Box | SAR 10.65 | Generic · Prescription | GOLDSHIELD PHARMACEUTICAL LTD | Valid |
| STELAZINE 5MG TABLETS | 5 mg | Tablet · Oral use | 50 Box | SAR 15.40 | Generic · Prescription | GOLDSHIELD PHARMACEUTICAL LTD | Valid |
| STELAZINE SPANSULES 10MG | 10 mg | Capsule · Oral use | 100 Blister | SAR 40.05 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
| STELAZINE SPANSULES 15MG | 15 mg | Capsule · Oral use | 100 Blister | SAR 54.80 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
| STELAZINE SPANSULES 2MG | 2 mg | Capsule · Oral use | 30 Blister | SAR 12.75 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
| STELAZINE SYRUP 1MG-5ML | 0.2 mg/ml | Syrup · Oral use | 1 Bottle | SAR 12.30 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
SCHIZOPHRENIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 1MG BASE | tablet · oral | SANDOZ | Prescription | 20 Nov 1981 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 2MG BASE | tablet · oral | SANDOZ | Prescription | 20 Nov 1981 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | SANDOZ | Prescription | 20 Nov 1981 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 5MG BASE | tablet · oral | SANDOZ | Prescription | 20 Nov 1981 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 1MG BASE; EQ 2MG BASE; EQ 5MG BASE; EQ 10MG BASE | tablet · oral | MYLAN | Prescription | 7 Jul 1997 |
| STELAZINE | EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | GLAXOSMITHKLINE | Discontinued | 16 Apr 1959 |
| STELAZINE | EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | GLAXOSMITHKLINE | Discontinued | 16 Apr 1959 |
| STELAZINE | EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | concentrate · oral | GLAXOSMITHKLINE | Discontinued | 16 Apr 1959 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 10MG BASE/ML | concentrate · oral | CHARTWELL RX | Discontinued | 15 Apr 1982 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 5MG BASE | tablet · oral | IVAX PHARMS | Discontinued | 19 Nov 1982 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 1MG BASE | tablet · oral | IVAX PHARMS | Discontinued | 19 Nov 1982 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 2MG BASE | tablet · oral | IVAX PHARMS | Discontinued | 19 Nov 1982 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | IVAX PHARMS | Discontinued | 19 Nov 1982 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 10MG BASE/ML | concentrate · oral | WOCKHARDT | Discontinued | 26 Jul 1983 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 1MG BASE | tablet · oral | DURAMED PHARMS BARR | Discontinued | 23 Apr 1985 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 2MG BASE | tablet · oral | DURAMED PHARMS BARR | Discontinued | 23 Apr 1985 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 5MG BASE | tablet · oral | DURAMED PHARMS BARR | Discontinued | 23 Apr 1985 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | DURAMED PHARMS BARR | Discontinued | 23 Apr 1985 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 1MG BASE; EQ 2MG BASE; EQ 5MG BASE; EQ 10MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 25 Oct 1996 |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 5MG BASE | tablet · oral | WATSON LABS | Discontinued | |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 1MG BASE | tablet · oral | WATSON LABS | Discontinued | |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 2MG BASE | tablet · oral | WATSON LABS | Discontinued | |
| TRIFLUOPERAZINE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | WATSON LABS | Discontinued | |
| TRIFLUOPERAZINE HCL | EQ 2MG BASE/ML | injectable · injection | QUAD PHARMS | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TRIFLUOPERAZINE 1 MG TABLET | $0.42513 | per EA | 23 Sep 2026 |
| US NADAC | TRIFLUOPERAZINE 10 MG TABLET | $1.24317 | per EA | 23 Sep 2026 |
| US NADAC | TRIFLUOPERAZINE 2 MG TABLET | $0.57869 | per EA | 23 Sep 2026 |
| US NADAC | TRIFLUOPERAZINE 5 MG TABLET | $0.86 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Trifluoperazine 1mg tablets | £108.56 | 112 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Trifluoperazine 1mg/5ml oral solution sugar free | £136.88 | 200 ml | 1 Oct 2026 |
| NHS Drug Tariff | Trifluoperazine 5mg tablets | £134.89 | 112 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Trifluoperazine 5mg/5ml oral solution sugar free | £74.49 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.